Improved survival with bevacizumab in advanced cervical cancer
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Uterine Cervical Neoplasms
The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).